http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 09 Jun 2026 09:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Providence+Swedish+Neuroscience+Institute+%28PSNI%29+Reaches+Milestone+in+Reducing+Global+Burden+of+Glioblastoma/26621219.html <div class="xn-content"> <p class="prntac">Ben and <span>Catherine Ivy Center for Advanced Brain Tumor Treatment</span> at PSNI collaborates with <location value="LU/us.wa.seatle" idsrc="xmltag.org" >Seattle</location>-based HDT Bio on preparations for trialing novel treatment to breach blood-brain barrier, and deliver proprietary immunotherapeutic directly into patients' tumors, rather than intravenously</p><p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- A collaboration involving <span>Providence Swedish Neuroscience Institute</span> (PSNI) recently concluded initial testing of a novel immunotherapy research project for the treatment of glioblastoma (GBM). This proprietary immunotherapeutic takes a unique approach to GBM treatment, maximizing the potential of a first-of-its-kind investigational agent by administering it directly into http://www.streetinsider.com/Press+Releases/Providence+Swedish+Neuroscience+Institute+%28PSNI%29+Reaches+Milestone+in+Reducing+Global+Burden+of+Glioblastoma/26621219.html Tue, 09 Jun 2026 09:00:00 -0400 A.06822034 CMV GBM O.20026344 PSNI http://www.streetinsider.com/Press+Releases/Providence+Swedish+Neuroscience+Institute+%28PSNI%29+Reaches+Milestone+in+Reducing+Global+Burden+of+Glioblastoma/26621219.html <div class="xn-content"> <p class="prntac">Ben and <span>Catherine Ivy Center for Advanced Brain Tumor Treatment</span> at PSNI collaborates with <location value="LU/us.wa.seatle" idsrc="xmltag.org" >Seattle</location>-based HDT Bio on preparations for trialing novel treatment to breach blood-brain barrier, and deliver proprietary immunotherapeutic directly into patients' tumors, rather than intravenously</p><p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- A collaboration involving <span>Providence Swedish Neuroscience Institute</span> (PSNI) recently concluded initial testing of a novel immunotherapy research project for the treatment of glioblastoma (GBM). This proprietary immunotherapeutic takes a unique approach to GBM treatment, maximizing the potential of a first-of-its-kind investigational agent by administering it directly into http://www.streetinsider.com/Press+Releases/Providence+Swedish+Neuroscience+Institute+%28PSNI%29+Reaches+Milestone+in+Reducing+Global+Burden+of+Glioblastoma/26621219.html Tue, 09 Jun 2026 09:00:00 -0400 A.06822034 CMV GBM O.20026344 PSNI http://www.streetinsider.com/Press+Releases/Providence+Swedish+Neuroscience+Institute+%28PSNI%29+Reaches+Milestone+in+Reducing+Global+Burden+of+Glioblastoma/26621219.html <div class="xn-content"> <p class="prntac">Ben and <span>Catherine Ivy Center for Advanced Brain Tumor Treatment</span> at PSNI collaborates with <location value="LU/us.wa.seatle" idsrc="xmltag.org" >Seattle</location>-based HDT Bio on preparations for trialing novel treatment to breach blood-brain barrier, and deliver proprietary immunotherapeutic directly into patients' tumors, rather than intravenously</p><p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- A collaboration involving <span>Providence Swedish Neuroscience Institute</span> (PSNI) recently concluded initial testing of a novel immunotherapy research project for the treatment of glioblastoma (GBM). This proprietary immunotherapeutic takes a unique approach to GBM treatment, maximizing the potential of a first-of-its-kind investigational agent by administering it directly into http://www.streetinsider.com/Press+Releases/Providence+Swedish+Neuroscience+Institute+%28PSNI%29+Reaches+Milestone+in+Reducing+Global+Burden+of+Glioblastoma/26621219.html Tue, 09 Jun 2026 09:00:00 -0400 A.06822034 CMV GBM O.20026344 PSNI http://www.streetinsider.com/Press+Releases/Providence+Swedish+Neuroscience+Institute+%28PSNI%29+Reaches+Milestone+in+Reducing+Global+Burden+of+Glioblastoma/26621219.html <div class="xn-content"> <p class="prntac">Ben and <span>Catherine Ivy Center for Advanced Brain Tumor Treatment</span> at PSNI collaborates with <location value="LU/us.wa.seatle" idsrc="xmltag.org" >Seattle</location>-based HDT Bio on preparations for trialing novel treatment to breach blood-brain barrier, and deliver proprietary immunotherapeutic directly into patients' tumors, rather than intravenously</p><p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- A collaboration involving <span>Providence Swedish Neuroscience Institute</span> (PSNI) recently concluded initial testing of a novel immunotherapy research project for the treatment of glioblastoma (GBM). This proprietary immunotherapeutic takes a unique approach to GBM treatment, maximizing the potential of a first-of-its-kind investigational agent by administering it directly into http://www.streetinsider.com/Press+Releases/Providence+Swedish+Neuroscience+Institute+%28PSNI%29+Reaches+Milestone+in+Reducing+Global+Burden+of+Glioblastoma/26621219.html Tue, 09 Jun 2026 09:00:00 -0400 A.06822034 CMV GBM O.20026344 PSNI http://www.streetinsider.com/Press+Releases/Providence+Swedish+Neuroscience+Institute+%28PSNI%29+Reaches+Milestone+in+Reducing+Global+Burden+of+Glioblastoma/26621219.html <div class="xn-content"> <p class="prntac">Ben and <span>Catherine Ivy Center for Advanced Brain Tumor Treatment</span> at PSNI collaborates with <location value="LU/us.wa.seatle" idsrc="xmltag.org" >Seattle</location>-based HDT Bio on preparations for trialing novel treatment to breach blood-brain barrier, and deliver proprietary immunotherapeutic directly into patients' tumors, rather than intravenously</p><p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- A collaboration involving <span>Providence Swedish Neuroscience Institute</span> (PSNI) recently concluded initial testing of a novel immunotherapy research project for the treatment of glioblastoma (GBM). This proprietary immunotherapeutic takes a unique approach to GBM treatment, maximizing the potential of a first-of-its-kind investigational agent by administering it directly into http://www.streetinsider.com/Press+Releases/Providence+Swedish+Neuroscience+Institute+%28PSNI%29+Reaches+Milestone+in+Reducing+Global+Burden+of+Glioblastoma/26621219.html Tue, 09 Jun 2026 09:00:00 -0400 A.06822034 CMV GBM O.20026344 PSNI http://www.streetinsider.com/PRNewswire/Providence+Swedish+Neuroscience+Institute+%28PSNI%29+Reaches+Milestone+in+Reducing+Global+Burden+of+Glioblastoma/26621219.html <div class="xn-content"> <p class="prntac">Ben and <span>Catherine Ivy Center for Advanced Brain Tumor Treatment</span> at PSNI collaborates with <location value="LU/us.wa.seatle" idsrc="xmltag.org" >Seattle</location>-based HDT Bio on preparations for trialing novel treatment to breach blood-brain barrier, and deliver proprietary immunotherapeutic directly into patients' tumors, rather than intravenously</p><p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- A collaboration involving <span>Providence Swedish Neuroscience Institute</span> (PSNI) recently concluded initial testing of a novel immunotherapy research project for the treatment of glioblastoma (GBM). This proprietary immunotherapeutic takes a unique approach to GBM treatment, maximizing the potential of a first-of-its-kind investigational agent by administering it directly into http://www.streetinsider.com/PRNewswire/Providence+Swedish+Neuroscience+Institute+%28PSNI%29+Reaches+Milestone+in+Reducing+Global+Burden+of+Glioblastoma/26621219.html Tue, 09 Jun 2026 09:00:00 -0400 A.06822034 CMV GBM O.20026344 PSNI http://www.streetinsider.com/PRNewswire/Providence+Swedish+Neuroscience+Institute+%28PSNI%29+Reaches+Milestone+in+Reducing+Global+Burden+of+Glioblastoma/26621219.html <div class="xn-content"> <p class="prntac">Ben and <span>Catherine Ivy Center for Advanced Brain Tumor Treatment</span> at PSNI collaborates with <location value="LU/us.wa.seatle" idsrc="xmltag.org" >Seattle</location>-based HDT Bio on preparations for trialing novel treatment to breach blood-brain barrier, and deliver proprietary immunotherapeutic directly into patients' tumors, rather than intravenously</p><p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- A collaboration involving <span>Providence Swedish Neuroscience Institute</span> (PSNI) recently concluded initial testing of a novel immunotherapy research project for the treatment of glioblastoma (GBM). This proprietary immunotherapeutic takes a unique approach to GBM treatment, maximizing the potential of a first-of-its-kind investigational agent by administering it directly into http://www.streetinsider.com/PRNewswire/Providence+Swedish+Neuroscience+Institute+%28PSNI%29+Reaches+Milestone+in+Reducing+Global+Burden+of+Glioblastoma/26621219.html Tue, 09 Jun 2026 09:00:00 -0400 A.06822034 CMV GBM O.20026344 PSNI http://www.streetinsider.com/PRNewswire/Providence+Swedish+Neuroscience+Institute+%28PSNI%29+Reaches+Milestone+in+Reducing+Global+Burden+of+Glioblastoma/26621219.html <div class="xn-content"> <p class="prntac">Ben and <span>Catherine Ivy Center for Advanced Brain Tumor Treatment</span> at PSNI collaborates with <location value="LU/us.wa.seatle" idsrc="xmltag.org" >Seattle</location>-based HDT Bio on preparations for trialing novel treatment to breach blood-brain barrier, and deliver proprietary immunotherapeutic directly into patients' tumors, rather than intravenously</p><p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- A collaboration involving <span>Providence Swedish Neuroscience Institute</span> (PSNI) recently concluded initial testing of a novel immunotherapy research project for the treatment of glioblastoma (GBM). This proprietary immunotherapeutic takes a unique approach to GBM treatment, maximizing the potential of a first-of-its-kind investigational agent by administering it directly into http://www.streetinsider.com/PRNewswire/Providence+Swedish+Neuroscience+Institute+%28PSNI%29+Reaches+Milestone+in+Reducing+Global+Burden+of+Glioblastoma/26621219.html Tue, 09 Jun 2026 09:00:00 -0400 A.06822034 CMV GBM O.20026344 PSNI http://www.streetinsider.com/PRNewswire/Providence+Swedish+Neuroscience+Institute+%28PSNI%29+Reaches+Milestone+in+Reducing+Global+Burden+of+Glioblastoma/26621219.html <div class="xn-content"> <p class="prntac">Ben and <span>Catherine Ivy Center for Advanced Brain Tumor Treatment</span> at PSNI collaborates with <location value="LU/us.wa.seatle" idsrc="xmltag.org" >Seattle</location>-based HDT Bio on preparations for trialing novel treatment to breach blood-brain barrier, and deliver proprietary immunotherapeutic directly into patients' tumors, rather than intravenously</p><p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- A collaboration involving <span>Providence Swedish Neuroscience Institute</span> (PSNI) recently concluded initial testing of a novel immunotherapy research project for the treatment of glioblastoma (GBM). This proprietary immunotherapeutic takes a unique approach to GBM treatment, maximizing the potential of a first-of-its-kind investigational agent by administering it directly into http://www.streetinsider.com/PRNewswire/Providence+Swedish+Neuroscience+Institute+%28PSNI%29+Reaches+Milestone+in+Reducing+Global+Burden+of+Glioblastoma/26621219.html Tue, 09 Jun 2026 09:00:00 -0400 A.06822034 CMV GBM O.20026344 PSNI http://www.streetinsider.com/PRNewswire/Providence+Swedish+Neuroscience+Institute+%28PSNI%29+Reaches+Milestone+in+Reducing+Global+Burden+of+Glioblastoma/26621219.html <div class="xn-content"> <p class="prntac">Ben and <span>Catherine Ivy Center for Advanced Brain Tumor Treatment</span> at PSNI collaborates with <location value="LU/us.wa.seatle" idsrc="xmltag.org" >Seattle</location>-based HDT Bio on preparations for trialing novel treatment to breach blood-brain barrier, and deliver proprietary immunotherapeutic directly into patients' tumors, rather than intravenously</p><p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- A collaboration involving <span>Providence Swedish Neuroscience Institute</span> (PSNI) recently concluded initial testing of a novel immunotherapy research project for the treatment of glioblastoma (GBM). This proprietary immunotherapeutic takes a unique approach to GBM treatment, maximizing the potential of a first-of-its-kind investigational agent by administering it directly into http://www.streetinsider.com/PRNewswire/Providence+Swedish+Neuroscience+Institute+%28PSNI%29+Reaches+Milestone+in+Reducing+Global+Burden+of+Glioblastoma/26621219.html Tue, 09 Jun 2026 09:00:00 -0400 A.06822034 CMV GBM O.20026344 PSNI http://www.streetinsider.com/Press+Releases/China+Minerals%3A+BC+Government%26apos%3Bs+Information+Note+Fails++to+Mention+Mineral+Rights+-+Amended+Petition+to+Be+Filed/11672375.html si-local-file:///var/storage/newsbody/2016/0525/11672375.html http://www.streetinsider.com/Press+Releases/China+Minerals%3A+BC+Government%26apos%3Bs+Information+Note+Fails++to+Mention+Mineral+Rights+-+Amended+Petition+to+Be+Filed/11672375.html Wed, 25 May 2016 08:58:00 -0400 A.36078215 CMV HWTHF http://www.streetinsider.com/Press+Releases/China+Minerals%3A+BC+Government%26apos%3Bs+Information+Note+Fails++to+Mention+Mineral+Rights+-+Amended+Petition+to+Be+Filed/11672375.html si-local-file:///var/storage/newsbody/2016/0525/11672375.html http://www.streetinsider.com/Press+Releases/China+Minerals%3A+BC+Government%26apos%3Bs+Information+Note+Fails++to+Mention+Mineral+Rights+-+Amended+Petition+to+Be+Filed/11672375.html Wed, 25 May 2016 08:58:00 -0400 A.36078215 CMV HWTHF http://www.streetinsider.com/Press+Releases/China+Minerals%3A+BC+Government%26apos%3Bs+Information+Note+Fails++to+Mention+Mineral+Rights+-+Amended+Petition+to+Be+Filed/11672375.html si-local-file:///var/storage/newsbody/2016/0525/11672375.html http://www.streetinsider.com/Press+Releases/China+Minerals%3A+BC+Government%26apos%3Bs+Information+Note+Fails++to+Mention+Mineral+Rights+-+Amended+Petition+to+Be+Filed/11672375.html Wed, 25 May 2016 08:58:00 -0400 A.36078215 CMV HWTHF http://www.streetinsider.com/Press+Releases/China+Minerals+Announces+Legal+Action+Against+Province+of+BC/11244552.html si-local-file:///var/storage/newsbody/2016/0125/11244552.html http://www.streetinsider.com/Press+Releases/China+Minerals+Announces+Legal+Action+Against+Province+of+BC/11244552.html Mon, 25 Jan 2016 16:41:00 -0400 A.32764620 A.36078215 CMV HWTHF http://www.streetinsider.com/Press+Releases/China+Minerals+Announces+Legal+Action+Against+Province+of+BC/11244552.html si-local-file:///var/storage/newsbody/2016/0125/11244552.html http://www.streetinsider.com/Press+Releases/China+Minerals+Announces+Legal+Action+Against+Province+of+BC/11244552.html Mon, 25 Jan 2016 16:41:00 -0400 A.32764620 A.36078215 CMV HWTHF http://www.streetinsider.com/Press+Releases/China+Minerals+Announces+Legal+Action+Against+Province+of+BC/11244552.html si-local-file:///var/storage/newsbody/2016/0125/11244552.html http://www.streetinsider.com/Press+Releases/China+Minerals+Announces+Legal+Action+Against+Province+of+BC/11244552.html Mon, 25 Jan 2016 16:41:00 -0400 A.32764620 A.36078215 CMV HWTHF http://www.streetinsider.com/Press+Releases/China+Minerals+Announces+Legal+Action+Against+Province+of+BC/11244552.html si-local-file:///var/storage/newsbody/2016/0125/11244552.html http://www.streetinsider.com/Press+Releases/China+Minerals+Announces+Legal+Action+Against+Province+of+BC/11244552.html Mon, 25 Jan 2016 16:41:00 -0400 A.32764620 A.36078215 CMV HWTHF http://www.streetinsider.com/Press+Releases/China+Minerals+Announces+Appointment+of+New+Director/10513600.html si-local-file:///var/storage/newsbody/2015/0501/10513600.html http://www.streetinsider.com/Press+Releases/China+Minerals+Announces+Appointment+of+New+Director/10513600.html Fri, 01 May 2015 16:30:00 -0400 A.10582719 CMV HWTHF http://www.streetinsider.com/Press+Releases/China+Minerals+Announces+Appointment+of+New+Director/10513600.html si-local-file:///var/storage/newsbody/2015/0501/10513600.html http://www.streetinsider.com/Press+Releases/China+Minerals+Announces+Appointment+of+New+Director/10513600.html Fri, 01 May 2015 16:30:00 -0400 A.10582719 CMV HWTHF http://www.streetinsider.com/Press+Releases/China+Minerals+Announces+Appointment+of+New+Director/10513600.html si-local-file:///var/storage/newsbody/2015/0501/10513600.html http://www.streetinsider.com/Press+Releases/China+Minerals+Announces+Appointment+of+New+Director/10513600.html Fri, 01 May 2015 16:30:00 -0400 A.10582719 CMV HWTHF http://www.streetinsider.com/Press+Releases/China+Minerals+Provides+Clarifying+Updates+on+Technical+Disclosure/10465810.html si-local-file:///var/storage/newsbody/2015/0416/10465810.html http://www.streetinsider.com/Press+Releases/China+Minerals+Provides+Clarifying+Updates+on+Technical+Disclosure/10465810.html Thu, 16 Apr 2015 16:15:00 -0400 A.10582719 CMV HWTHF http://www.streetinsider.com/Press+Releases/China+Minerals+Provides+Clarifying+Updates+on+Technical+Disclosure/10465810.html si-local-file:///var/storage/newsbody/2015/0416/10465810.html http://www.streetinsider.com/Press+Releases/China+Minerals+Provides+Clarifying+Updates+on+Technical+Disclosure/10465810.html Thu, 16 Apr 2015 16:15:00 -0400 A.10582719 CMV HWTHF http://www.streetinsider.com/Press+Releases/China+Minerals+Provides+Clarifying+Updates+on+Technical+Disclosure/10465810.html si-local-file:///var/storage/newsbody/2015/0416/10465810.html http://www.streetinsider.com/Press+Releases/China+Minerals+Provides+Clarifying+Updates+on+Technical+Disclosure/10465810.html Thu, 16 Apr 2015 16:15:00 -0400 A.10582719 CMV HWTHF